Tanguay, Megane et al. published their research in Vaccine in 2022 | CAS: 16506-27-7

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).COA of Formula: C16H21Cl2N3O2

B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders was written by Tanguay, Megane;Boutin, Marianne;Laumaea, Annemarie;Salaciak, Matthew;Mendoza, Alma;Cassis, Chantal;Ajjamada, Lissa;Assouline, Sarit;Patenaude, Francois;Clark, Michael Webster;Finzi, Andres;Johnson, Nathalie A.. And the article was included in Vaccine in 2022.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. The relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients was investigated . Anti-RBD antibodies and the lymphocyte immunophenotype in 19 controls, 22 lymphoma patients on observation (cohort 1) and 55 lymphoma patients receiving their vaccines post B-cell depleting therapy (cohort 2) was measured. Half of the lymphoma patients in both cohorts achieved seropositivity compared to 100% of controls. In cohort 2, only 5% achieved an antibody response in the first year post B-cell depleting treatment, vs 88% treated >2 years prior. Also, 28% of patients with <50 B cells/μl achieved a serol. response vs 86% of patients with B-cell >50 B cells/μl. B-cell cytopenia is profound within the first year of exposure to B-cell depleting treatment, therefore an addnl. dose of vaccine within that timeframe is unlikely to raise antibody levels. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem